GlassScriptPhysician profile
Rima Nitinchandra Vaidya
NPI 1477327815
$1,029.59
in general payments reported to CMS, 2019-2025
15 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $67.81 · 2024: $605 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.60 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $245.25 | 2024-2025 | |
| Abbvie INC. | $155.66 | 2023-2025 | |
| Astellas Pharma US INC | $109.57 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $85.14 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $71.38 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $70.92 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $69.49 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $62.54 | 2024-2025 | Repatha, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $41.60 | 2024-2025 | |
| Novo Nordisk INC | $39.90 | 2025 | Wegovy, Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $18.67 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $16.76 | 2025 | Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $14.26 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.24 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.21 | 2024 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rima Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.